Claims for Patent: 10,695,350

Summary for Patent: 10,695,350

Title:	Methods of treating and preventing graft versus host disease
Abstract:	Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventor(s):	John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
Assignee:	Pharmacyclics LLC
Application Number:	US16/582,945
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,695,350
Patent Claims:	1. A method for achieving a complete resolution of symptoms of chronic graft versus host disease (GVHD) in an adult patient having chronic GVHD refractory to systemic therapy comprising orally administering 420 mg of ibrutinib once per day to the adult patient having chronic GVHD refractory to systemic therapy, thereby achieving complete resolution of the symptoms of refractory chronic GVHD in the adult patient, and discontinuing administering ibrutinib when the adult patient no longer requires therapy for the chronic GVHD. 2. The method of claim 1, wherein the adult patient achieves full donor chimerism prior to the discontinuing administering ibrutinib. 3. A method for achieving a complete resolution of symptoms of chronic graft versus host disease (GVHD) and preventing recurrence of a hematological malignancy in an adult patient having chronic GVHD refractory to systemic therapy and a hematological malignancy comprising orally administering 420 mg of ibrutinib once per day to the adult patient, thereby achieving complete resolution of the symptoms of refractory chronic GVHD in the adult patient and preventing recurrence of the hematological malignancy. 4. The method of claim 3, wherein the adult patient achieves full donor chimerism. 5. The method of claim 4, wherein the hematological malignancy is refractory CLL. 6. The method of claim 5, wherein the adult patient was treated with an allogenic hematopoietic cell transplant. 7. The method of claim 6, wherein the chronic GVHD is oral cGVHD of the oropharyngeal region. 8. The method of claim 7, wherein the adult patient has received a prior anticancer agent, wherein the anticancer treatment is rituximab.